文献速递小儿神经外科与脑积水神经重症

神经内镜下中脑水管成形术治疗特发性中脑水管狭窄相关脑积水的长期可靠性

Long-Term Reliability of Neuroendoscopic Aqueductoplasty in Idiopathic Aqueductal Stenosis-Related Hydrocephalus.
PubMed 文献 · Neurosurgery · 2019-01-01

该研究对1996年至2002年间在本院接受神经内镜下中脑水管成形术(AP)治疗特发性中脑水管狭窄(iAS)的患者进行长期随访临床检查和磁共振(MR)成像,评估AP的长期疗效。17例患者平均随访120个月,临床相关的中脑水管再闭合发生率为11/17,AP总体失败率为88.2%。结论认为AP长期失败风险高,不推荐作为iAS所致脑积水的首选治疗,应改行内镜下第三脑室造瘘术(ETV)。

要点

  • AP治疗iAS的总体失败率为88.2%,失败均匀分布于整个随访期。
  • 17例患者中11例出现临床相关中脑水管再闭合,均改行ETV并获成功。
  • AP不推荐作为iAS所致脑积水的首选治疗,应改行ETV。

核心结论

  • AP在长期随访中有很高的失败风险,不推荐作为iAS所致脑积水的首选治疗,应改行ETV。
  • AP可保留用于少数无法行ETV的患者,但应联合支架置入以避免中脑水管再闭合。

研究设计与样本

  • 对1996年至2002年间在本院接受AP治疗iAS的患者进行长期随访临床检查和磁共振(MR)成像。
  • 共治疗20例患者(14例女性,6例男性,平均年龄41.7岁,范围0.5-67岁)。
  • 2例失访,1例在AP后6个月死亡但与手术无关,其余17例平均随访120个月。

主要发现

  • 17例患者中11例在平均随访53.4个月后出现临床相关的中脑水管再闭合,这些患者均接受了ETV并在进一步随访中成功。
  • 其余6例患者中4例虽MR成像显示中脑水管再狭窄但无临床症状。
  • AP的总体失败率为88.2%,失败均匀分布于整个随访期。

临床怎么用

  • 作者认为AP不推荐作为iAS所致脑积水的首选治疗,应改行ETV。
  • 作者认为AP可保留用于少数无法行ETV的患者,但应联合支架置入以避免中脑水管再闭合。

局限性

  • 2例患者失访。
  • 1例患者在AP后6个月死亡但与手术无关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: During the 1990s, endoscopic aqueductoplasty (AP) was considered to be a valuable alternative to endoscopic third ventriculostomy (ETV) in treating hydrocephalus related to idiopathic aqueductal stenosis (iAS), with promising short-term outcomes. OBJECTIVE: To evaluate the long-term outcome of AP in the treatment of iAS. METHODS: Long-term follow-up clinical examinations and magnetic resonance (MR) imaging were performed for patients treated by an AP for iAS in our department. RESULTS: Twenty patients (14 female, 6 male, mean age 41.7 yr, range 0.5-67 yr) were treated between 1996 and 2002. Two patients were lost to long-term follow-up. One patient died 6 mo after AP, but death was not related to the procedure. The mean follow-up for the remaining 17 patients was 120 mo. Clinically relevant aqueductal reclosure was observed in 11/17 patients after a mean follow-up of 53.4 mo. These 11 patients underwent ETV, which has been successful during further follow-up. Four of the six remaining patients presented with no clinical symptoms, although aqueductal restenosis was observed on MR imaging. Thus, the overall failure rate of AP was 88.2%. The failures were homogeneously distributed over the entire follow-up period. CONCLUSION: AP has a high risk of failure during long-term follow-up and is not recommended as the first choice of treatment in hydrocephalus caused by iAS. ETV should be done instead. AP may be reserved for a limited number of patients in whom ETV is not feasible but should be combined with stenting to avoid reclosure of the aqueduct.

来源:Neurosurgery,查看原文。版权归原作者所有。

引用

  1. Marx S, Baldauf J, Matthes M, et al. Long-Term Reliability of Neuroendoscopic Aqueductoplasty in Idiopathic Aqueductal Stenosis-Related Hydrocephalus. Neurosurgery. 2019. PMID: 29878198. doi:10.1093/neuros/nyy219

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。